Explained: How the Moderna vaccine stacks up against Pfizer-BioNTech's
India TodayUS regulators authorized Moderna Inc's Covid-19 vaccine for emergency use on Friday, a week after granting the first US authorization to Pfizer Inc and BioNTech SE's coronavirus shot. Very few participants who received the vaccine in either trial got sick with COVID-19 and almost none got seriously ill. Data the companies have submitted to the Food and Drug Administration suggest that they start offering partial protection against Covid-19 around two weeks after recipients receive their first dose. While the vaccines have not been compared head-to-head, Moderna's vaccine appears to be associated with slightly more severe cases of fatigue, headache and fever in the day or two following the second shot, especially in people younger than 65. Britain's medical regulator has said anyone with a history of anaphylaxis, or severe allergic reactions to a medicine or food should not get the Pfizer/BioNTech Covid-19 vaccine.